Globus Medical, Inc. GMED

Full chart Compare
Set alert

Price alert · GMED

All alert types
79.58 USD +0.12 (+0.15%)

At closeNov 4, 2026, 7:22 AM EST

79.35 -0.23 -0.29%

Pre-market · Nov 4, 7:22 AM ET

78.61 Day range 80.20
60.26 52-week range 101.40
YTD
-8.85%
1 year
+29.06%
Market cap
10.68B
Revenue (ttm)
3.14B
Profit margin
17.03%
EPS (ttm)
3.90
Shares out
111.83M
P/E ratio
20.41
Forward P/E
14.76
YTD return
-8.85%
1-year return
+29.06%
Volume
1.42M
Avg volume
1.43M
Open
78.64
Previous close
79.46
Day's range
78.61 – 80.20
52-week range
60.26 – 101.40
Beta
0.95
Analysts
Buy
Price target
100.92 (+26.8%)
Earnings date
Nov 5, 2026

3M -1.93 (-2.37%)

758085Aug 12Aug 31Sep 18Oct 7Oct 2679.58

Key statistics

Enterprise value
10.19B
PEG ratio
1.49
Price / sales
3.40
Price / book
2.24
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
5.90%
Free cash flow
554.19M
Total cash
595.14M
Total debt
111.91M
Return on equity
11.81%
Short % of float
7.38%
50-day average
77.47
200-day average
83.42

Financials — quick view

All financials
GMED Revenue — quarterly 789.61M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
GMED Net income — quarterly 151.57M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
GMED EPS — quarterly 1.12
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

GMED recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20261.20———
Aug 6, 2026Jun 30, 20261.101.34+0.24+21.82%
May 7, 2026Mar 31, 20260.921.12+0.20+21.74%
Feb 24, 2026Dec 31, 20251.061.28+0.22+20.75%
Nov 6, 2025Sep 30, 20250.7811.18+0.40+51.09%
Aug 7, 2025Jun 30, 20250.760.86+0.10+13.16%

Upgrades / downgrades

GMED analyst upgrades and downgrades
DateFirmActionFromTo
Oct 1, 2026RBC CapitalmainOutperformOutperform
Aug 7, 2026Wells FargomainOverweightOverweight
Jul 28, 2026UBSinit—Neutral
Jul 16, 2026Truist SecuritiesmainBuyBuy
Jul 13, 2026RBC CapitalmainOutperformOutperform
Jul 9, 2026BMO Capitalinit—Outperform

About Globus Medical, Inc.

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on GMED — it syncs with the Stock Master app.

Insider holders

GMED insider holders
InsiderRelationLatest transactionDateShares held
DAVIDAR DAVID DDirectorStock GiftJul 26, 2026673,642
KLINE KYLEChief Financial OfficerSaleJan 7, 20260
LEMAITRE DANIELDirectorSaleNov 21, 20240
NORWALK LESLIE VDirectorSaleJan 7, 202610,419
PAUL DAVID COfficer, Director and Beneficial OwnerConversion of Exercise of derivative securityDec 7, 202560,417
PFEIL KEITH W.Chief Operating OfficerSaleJan 9, 20250

Institution ownership

GMED institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.05%10,806,724859.89MJun 29, 2026
Jupiter Topco LLC6.11%8,200,423652.51MJun 29, 2026
Vanguard Capital Management LLC3.80%5,107,532406.41MJun 29, 2026
Vanguard Portfolio Management LLC3.72%4,994,385397.40MJun 29, 2026
Invesco Ltd.3.21%4,309,771342.93MJun 29, 2026
Kayne Anderson Rudnick Investment Management LLC3.19%4,279,730340.54MJun 29, 2026

Fund ownership

GMED fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF2.97%3,983,485316.97MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.68%3,595,564286.10MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.93%2,597,815206.71MJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund1.64%2,207,141175.62MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.11%1,496,500119.08MJun 29, 2026
J.P. Morgan Fleming Mutual Fd. Group, Inc.-JPMorgan Mid Cap Value Fd.1.10%1,475,978117.44MJun 29, 2026